Why Ipamorelin replaced GHRP-2 and GHRP-6

If you read strength-peptide protocols from ten or fifteen years ago, GHRP-2 and GHRP-6 show up everywhere. Read protocols today and Ipamorelin has effectively pushed both out of the conversation. The shift was not driven by a marketing campaign — it was driven by a cleaner side-effect profile and a more selective mechanism. This deep-dive walks through what each compound actually does, why Ipamorelin won, and where GHRP-2 or GHRP-6 might still make sense for a particular user.

The short version: Ipamorelin produces GH release without meaningfully raising cortisol, prolactin, or appetite. The older GHRPs do raise those secondary signals. Once a cleaner option became available, the older ones became hard to justify for most use cases.

What ghrelin mimetics actually do

All three compounds — Ipamorelin, GHRP-2, and GHRP-6 — bind the GHS-R1a receptor, the same receptor that the body's natural ghrelin binds. Activating that receptor on the pituitary triggers GH release. Activating it elsewhere produces other effects: hunger signaling in the hypothalamus, ACTH and cortisol release from secondary pathways, and prolactin release in some contexts.

The interesting question is selectivity. A clean ghrelin mimetic activates only the GH-release pathway. A messy one activates several pathways at once. That is the axis that separates Ipamorelin from the older GHRPs.

The pattern is straightforward. Ipamorelin gives you the GH release without the secondary effects. The older GHRPs give you the GH release plus complications most users would rather avoid.

How GHRP-6 was used

GHRP-6 was the first ghrelin mimetic in widespread use. It produces a strong GH pulse and a strong appetite response. That second effect — pronounced hunger within 20 to 30 minutes of injection — was a feature for users trying to gain weight in lean phases and a serious problem for users trying to lose fat.

The cortisol and prolactin elevations are smaller than GHRP-2's but not negligible. Long-term, the appetite issue made GHRP-6 hard to use in any kind of cutting protocol, and the secondary hormonal noise was an unnecessary cost when the goal was simply GH and IGF-1 elevation.

GHRP-6 still has a niche today: users who specifically want appetite stimulation, often as part of a deliberate gaining phase. Outside that narrow case, it is hard to justify when Ipamorelin exists.

How GHRP-2 was used

GHRP-2 produces the strongest GH pulse of the three on a per-microgram basis. It also produces the most pronounced cortisol and prolactin rises. For a window in the late 2000s and early 2010s, it was the default ghrelin mimetic in many protocols, often paired with CJC-1295 in the same way Ipamorelin is paired today.

The problem with GHRP-2 was not the GH side. It was the cortisol and prolactin side. Cortisol elevation, repeated daily over weeks, is not what most users running a recovery or body-composition protocol want. Prolactin elevation has its own unwanted-effect profile — water retention, libido changes, and in some users gynecomastia-related concerns when combined with other compounds.

For users prioritizing the cleanest possible GH signal, the GHRP-2 trade-offs became indefensible once Ipamorelin was widely available.

What made Ipamorelin different

Ipamorelin was developed specifically with selectivity in mind. The goal was to engage GHS-R1a and trigger GH release without the off-target secondary signaling. The pre-clinical record on Ipamorelin consistently shows:

• A robust GH pulse comparable to the older GHRPs at standard doses
• Cortisol levels essentially unchanged from baseline
• Prolactin levels essentially unchanged from baseline
• Appetite changes mild and transient

That combination — equivalent GH effect, dramatically cleaner secondary profile — is what won the category. Once Ipamorelin became cheap and widely available through the same vendor channels as GHRP-2 and GHRP-6, the older compounds lost their reason to exist for most users.

Why selectivity matters more than people realize

It is easy to underweight the difference between "raises cortisol a little" and "doesn't raise cortisol." If you are running a peptide protocol for months at a time, two or three injections per day, every small secondary effect compounds. A 10 percent cortisol bump, repeated three times daily for twelve weeks, is meaningfully different from no bump at all.

The same logic applies to prolactin and appetite. Each one of those secondary effects, on its own, is manageable. Stacked across weeks and combined with the other compounds in a typical protocol, they shape the experience in ways that make the older GHRPs measurably worse to live with.

The cleaner the signal, the cleaner the protocol's interpretability. If something feels off on Ipamorelin plus CJC-1295, you have one suspect. If something feels off on GHRP-2 plus CJC-1295, you have several.

The practical comparison

Where each one fits today:

Ipamorelin is not strictly superior in every dimension — GHRP-2 produces a slightly larger GH pulse, and GHRP-6 is genuinely useful when appetite stimulation is the point. But for the majority of strength-peptide users, the question is "which clean GH-axis support do I run," and Ipamorelin answers it.

For a deeper comparison protocol-by-protocol, see GHRP-2 vs GHRP-6 vs Ipamorelin.

The Ipamorelin plus CJC-1295 default

The reason Ipamorelin became the default ghrelin mimetic is partly that it pairs cleanly with CJC-1295 (no DAC). The two activate complementary pathways — Ipamorelin via GHS-R1a, CJC-1295 via the GHRH receptor — and the combined pulse is larger and cleaner than either alone.

A typical protocol:

Most users dose before bed to align with the body's natural strongest GH pulse, with optional second and third doses earlier in the day or around training.

If you swap Ipamorelin for GHRP-2 in that stack, you get a slightly larger GH pulse plus cortisol and prolactin elevation. If you swap Ipamorelin for GHRP-6, you get the appetite increase as a bonus or a problem, depending on goals. Most users prefer the clean version.

What the older GHRPs got right

A fair note: GHRP-2 and GHRP-6 are not bad compounds. The pharmacology works. They do produce real GH release. They have decades of pre-clinical and limited clinical data. The reason they fell out of favor is not that they failed — it is that a cleaner option emerged. Compounds get displaced when something better arrives, not when they are revealed to be broken.

If Ipamorelin had never been developed, GHRP-2 plus CJC-1295 would still be a reasonable protocol with a manageable side-effect profile. The shift to Ipamorelin is best understood as a quality-of-life upgrade rather than a discovery that the older GHRPs were dangerous.

What the long-term picture looks like

Worth noting: long-term human data is thin for all three compounds. Ipamorelin's cleaner short-term profile does not automatically translate to a known better long-term profile. The same caveats that apply to any GH-axis-active compound apply here:

• IGF-1 elevation has theoretical cancer concerns, especially for users with relevant history
• Insulin sensitivity can shift over months of use
• Pituitary feedback dynamics in chronic use are under-studied

The case for Ipamorelin over older GHRPs rests on the shorter-term selectivity advantage, not on long-term safety data that nobody has.

Practical takeaway

Ipamorelin replaced GHRP-2 and GHRP-6 because it does the same primary job — GH release via the ghrelin receptor — without raising cortisol, prolactin, or appetite the way the older compounds do. The shift is real, the rationale is mechanism-level, and for most modern users the choice is straightforward.

The older compounds are not gone. GHRP-6 still has a hunger-stimulation use case, and GHRP-2 still produces the largest GH pulse per microgram. But for the default GH-axis support protocol — the kind most strength-peptide users actually run — Ipamorelin is the cleaner answer, and the category has settled around it.

Related reading

• GH secretagogues complete guide
• Ipamorelin protocol
• GHRP-2 vs GHRP-6 vs Ipamorelin
• CJC-1295 with vs without DAC
• Best injection timing